GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » ROC (Joel Greenblatt) %

Day One Biopharmaceuticals (Day One Biopharmaceuticals) ROC (Joel Greenblatt) % : -39,188.15% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Day One Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -39,188.15%.

The historical rank and industry rank for Day One Biopharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

DAWN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -32222.67   Med: -24131.06   Max: -2853.42
Current: -30894.15

During the past 5 years, Day One Biopharmaceuticals's highest ROC (Joel Greenblatt) % was -2853.42%. The lowest was -32222.67%. And the median was -24131.06%.

DAWN's ROC (Joel Greenblatt) % is ranked worse than
96.53% of 1470 companies
in the Biotechnology industry
Industry Median: -338.875 vs DAWN: -30894.15

Day One Biopharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Day One Biopharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for Day One Biopharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals ROC (Joel Greenblatt) % Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
- -2,853.42 -18,968.19 -29,293.92 -32,222.67

Day One Biopharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21,133.75 -26,072.49 -28,125.05 -30,080.70 -39,188.15

Competitive Comparison of Day One Biopharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Day One Biopharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Day One Biopharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's ROC (Joel Greenblatt) % falls into.



Day One Biopharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 7.753) - (23.629 + 0 + 0.409)
=-16.285

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 8.927) - (28.059 + 0 + 1.041)
=-20.173

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Day One Biopharmaceuticals for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-238.068/( ( (0.655 + max(-16.285, 0)) + (0.56 + max(-20.173, 0)) )/ 2 )
=-238.068/( ( 0.655 + 0.56 )/ 2 )
=-238.068/0.6075
=-39,188.15 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Day One Biopharmaceuticals  (NAS:DAWN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Day One Biopharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Executives
York Charles N Ii officer: COO, CFO and Secretary 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Samuel C. Blackman officer: Chief Medical Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Jeremy Bender director, officer: Chief Executive Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Ai Day 1 Llc 10 percent owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p. 10 percent owner 2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone director 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John A. Josey director C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Day One Biopharmaceuticals Inc Shares

By GuruFocus Research GuruFocus Editor 05-19-2023

Insider Alert: An Insider Just Sold Day One Biopharmaceuticals Inc Shares

By GuruFocus Research GuruFocus Editor 01-24-2023

Day One Announces Proposed Public Offering of Common Stock

By sperokesalga sperokesalga 06-06-2023